Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma

por Budden, Timothy, van der Westhuizen, Andre, Bowden, Nikola A.
Publicado 2018

Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy

por Wong-Brown, Michelle W., van der Westhuizen, Andre, Bowden, Nikola A.
Publicado 2022

Pilot early phase II study of decitabine and carboplatin in patients with advanced melanoma

por van der Westhuizen, Andre, Knoblauch, Naomi, Graves, Moira C., Levy, Richard, Vilain, Ricardo E., Bowden, Nikola A.
Publicado 2020

Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers

por Navani, Vishal, Graves, Moira C., Marchett, Giovana Celli, Mandaliya, Hiren, Bowden, Nikola A., van der Westhuizen, Andre
Publicado 2021

Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles

por Graves, Moira, CelliMarchett, Giovana, van Zyl, Belinda, Tang, Denise, Vilain, Ricardo E., van der Westhuizen, Andre, Bowden, Nikola A.
Publicado 2019

Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade–resistant Melanoma for Anti-PD-L1 Rechallenge

por van der Westhuizen, Andre, Lyle, Megan, Graves, Moira C., Zhu, Xiaoqiang, Wong, Jason W. H., Cornall, Kerrie, Ren, Shu, Pugliese, Leanna, Levy, Richard, Majid, Adeeb, Vilain, Ricardo E., Bowden, Nikola A.
Publicado 2022

Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clini...

por Day, Fiona, Sridharan, Swetha, Lynam, James, Gedye, Craig, Johnson, Catherine, Fraser, Allison, Thompson, Stephen R., Michael, Michael, Leong, Trevor, Roy, Amitesh, Kumar, Mahesh, van der Westhuizen, Andre, Quah, Gaik T., Mandaliya, Hiren, Mallesara, Girish, Sappiatzer, Joshua, Oldmeadow, Christopher, Martin, Jarad
Publicado 2022

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

por Yap, Timothy A., Vieito, Maria, Baldini, Capucine, Sepúlveda-Sánchez, Juan Manuel, Kondo, Shunsuke, Simonelli, Matteo, Cosman, Rasha, van der Westhuizen, Andre, Atkinson, Victoria, Carpentier, Antoine F., Löhr, Mario, Redman, Rebecca, Mason, Warren, Cervantes, Andres, Le Rhun, Emilie, Ochsenreither, Sebastian, Warren, Louise, Zhao, Yumin, Callies, Sophie, Estrem, Shawn T., Man, Michael, Gandhi, Leena, Avsar, Emin, Melisi, Davide
Publicado 2021

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

por Bendell, Johanna C., Sauri, Tamara, Gracián, Antonio Cubillo, Alvarez, Rafael, López‐López, Carlos, García‐Alfonso, Pilar, Hussein, Maen, Miron, Maria‐Luisa Limon, Cervantes, Andrés, Montagut, Clara, Vivas, Cristina Santos, Bessudo, Alberto, Plezia, Patricia, Moons, Veerle, Andel, Johannes, Bennouna, Jaafar, van der Westhuizen, Andre, Samuel, Leslie, Rossomanno, Simona, Boetsch, Christophe, Lahr, Angelika, Franjkovic, Izolda, Heil, Florian, Lechner, Katharina, Krieter, Oliver, Hurwitz, Herbert
Publicado 2019

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis

por Bhave, Prachi, Pallan, Lalit, Long, Georgina V., Menzies, Alexander M., Atkinson, Victoria, Cohen, Justine V., Sullivan, Ryan J., Chiarion-Sileni, Vanna, Nyakas, Marta, Kahler, Katharina, Hauschild, Axel, Plummer, Ruth, Trojaniello, Claudia, Ascierto, Paolo A., Zimmer, Lisa, Schadendorf, Dirk, Allayous, Clara, Lebbe, Celeste, Maurichi, Andrea, Santinami, Mario, Roy, Severine, Robert, Caroline, Lesimple, Thierry, Patel, Sapna, Versluis, Judith M., Blank, Christian U., Khattak, Adnan, Van der Westhuizen, Andre, Carlino, Matteo S., Shackleton, Mark, Haydon, Andrew
Publicado 2020

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

por Weber, Jeffrey S., Schadendorf, Dirk, Del Vecchio, Michele, Larkin, James, Atkinson, Victoria, Schenker, Michael, Pigozzo, Jacopo, Gogas, Helen, Dalle, Stéphane, Meyer, Nicolas, Ascierto, Paolo A., Sandhu, Shahneen, Eigentler, Thomas, Gutzmer, Ralf, Hassel, Jessica C., Robert, Caroline, Carlino, Matteo S., Di Giacomo, Anna Maria, Butler, Marcus O., Muñoz-Couselo, Eva, Brown, Michael P., Rutkowski, Piotr, Haydon, Andrew, Grob, Jean-Jacques, Schachter, Jacob, Queirolo, Paola, de la Cruz-Merino, Luis, van der Westhuizen, Andre, Menzies, Alexander M., Re, Sandra, Bas, Tuba, de Pril, Veerle, Braverman, Julia, Tenney, Daniel J., Tang, Hao, Long, Georgina V.
Publicado 2023